SI1441701T1 - Formulacija granul montelukasta - Google Patents
Formulacija granul montelukastaInfo
- Publication number
- SI1441701T1 SI1441701T1 SI200230670T SI200230670T SI1441701T1 SI 1441701 T1 SI1441701 T1 SI 1441701T1 SI 200230670 T SI200230670 T SI 200230670T SI 200230670 T SI200230670 T SI 200230670T SI 1441701 T1 SI1441701 T1 SI 1441701T1
- Authority
- SI
- Slovenia
- Prior art keywords
- granule formulation
- montelukast
- montelukast granule
- formulation
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33954901P | 2001-10-26 | 2001-10-26 | |
EP02801836A EP1441701B1 (en) | 2001-10-26 | 2002-10-22 | Montelukast granule formulation |
PCT/CA2002/001604 WO2003035036A1 (en) | 2001-10-26 | 2002-10-22 | Montelukast granule formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1441701T1 true SI1441701T1 (sl) | 2008-08-31 |
Family
ID=23329547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200230670T SI1441701T1 (sl) | 2001-10-26 | 2002-10-22 | Formulacija granul montelukasta |
Country Status (26)
Country | Link |
---|---|
US (2) | US20030096840A1 (sl) |
EP (1) | EP1441701B1 (sl) |
JP (1) | JP4420671B2 (sl) |
KR (1) | KR101094084B1 (sl) |
CN (1) | CN100591329C (sl) |
AT (1) | ATE385781T1 (sl) |
AU (1) | AU2002333134B2 (sl) |
BR (1) | BR0213477A (sl) |
CA (1) | CA2463947C (sl) |
CY (1) | CY1107400T1 (sl) |
DE (1) | DE60225040T2 (sl) |
DK (1) | DK1441701T3 (sl) |
EC (1) | ECSP045082A (sl) |
EG (1) | EG24380A (sl) |
ES (1) | ES2298431T3 (sl) |
HR (1) | HRP20040367B1 (sl) |
HU (1) | HUP0401670A3 (sl) |
IL (1) | IL161299A0 (sl) |
MX (1) | MXPA04003856A (sl) |
MY (1) | MY148466A (sl) |
NO (1) | NO20042167L (sl) |
PE (1) | PE20030638A1 (sl) |
PT (1) | PT1441701E (sl) |
SI (1) | SI1441701T1 (sl) |
WO (1) | WO2003035036A1 (sl) |
ZA (1) | ZA200402584B (sl) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040192660A1 (en) * | 2003-03-12 | 2004-09-30 | Mullally John P. | Protocol for improving vision |
AU2006224842B2 (en) * | 2005-03-16 | 2011-09-29 | Meda Pharma Gmbh & Co Kg | The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases |
AU2006317530B2 (en) | 2005-11-28 | 2011-09-01 | Imaginot Pty Ltd | Oral therapeutic compound delivery system |
PL1976522T5 (pl) | 2005-12-30 | 2019-12-31 | Krka Tovarna Zdravil, D.D., Novo Mesto | Kompozycja farmaceutyczna zawierająca montelukast |
DK1818057T3 (da) * | 2006-02-09 | 2010-07-19 | Teva Pharma | Stabile farmaceutiske sammensætninger af montelukast-natrium |
CN101516334B (zh) | 2006-09-26 | 2013-07-10 | 塔罗制药北美有限公司 | 用于抗生素的稳定组合物以及应用方法 |
CA2719246A1 (en) * | 2008-03-26 | 2009-10-01 | Taro Pharmaceuticals North America, Inc. | Stabilizing lipid compositions for oral pharmaceutical agents |
US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
LT2712622T (lt) | 2008-05-21 | 2016-09-26 | Ferring B.V. | Burnoje disperguojamas desmopresinas, skirtas nikturijos netrikdomo miego pirminio periodo pailginimui |
WO2009153305A2 (en) * | 2008-06-19 | 2009-12-23 | Sandoz Ag | Pharmaceutical compositions of montelukast sodium |
US8895141B2 (en) | 2008-08-18 | 2014-11-25 | Mitsubishi Shoji Foodtech Co., Ltd. | Excipient for compressed tablets comprising novel spherical mannitol |
JO3112B1 (ar) | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
MX350447B (es) | 2010-03-29 | 2017-09-07 | Ferring Bv | Composicion farmaceutica de disolucion rapida. |
FR2967066B1 (fr) * | 2010-11-04 | 2013-06-14 | Ethypharm Sa | Utilisation par voie sublinguale de microgranules non comprimes |
CN102085187B (zh) * | 2011-01-27 | 2012-01-11 | 海南美大制药有限公司 | 孟鲁司特钠脂质体固体制剂 |
JP6038914B2 (ja) | 2011-07-26 | 2016-12-07 | スン プハルマ アドバンセド リサーチ カンパニー リミテド | キノリン−、キノキサリン、又はベンゾチアゾールベースのシステイニルロイコトリエンアンタゴニスト(ltc4) |
RU2633640C2 (ru) | 2011-09-16 | 2017-10-16 | Ферринг Б.В. | Быстрорастворимая фармацевтическая композиция |
WO2013077829A1 (en) | 2011-11-21 | 2013-05-30 | Mahmut Bilgic | Water-soluble pharmaceutical granules |
US9999590B2 (en) * | 2012-07-12 | 2018-06-19 | Ferring B.V. | Diclofenac formulations |
WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
US20140072628A1 (en) * | 2012-09-12 | 2014-03-13 | Glenmark Generics Ltd. | Stable pharmaceutical composition of saxagliptin |
CN103520129B (zh) * | 2013-10-15 | 2020-07-31 | 天垚医药科技发展(上海)有限公司 | 一种孟鲁斯特钠脉冲释放制剂 |
CN103520136B (zh) * | 2013-10-15 | 2020-07-31 | 天垚医药科技发展(上海)有限公司 | 孟鲁斯特钠脉冲胶囊及其制备方法 |
CN103520130B (zh) * | 2013-10-15 | 2020-08-04 | 天垚医药科技发展(上海)有限公司 | 孟鲁斯特钠择时控释片及其制备方法 |
CN104644564A (zh) * | 2013-11-25 | 2015-05-27 | 天津汉瑞药业有限公司 | 一种含孟鲁司特钠的稳定的颗粒制剂及其制备方法 |
CN103655497B (zh) * | 2013-12-18 | 2018-05-29 | 北京华禧联合科技发展有限公司 | 一种孟鲁司特钠口腔崩解片及其制备方法 |
CA2936332A1 (en) | 2014-01-22 | 2015-07-30 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier) |
CN103720672B (zh) * | 2014-01-26 | 2016-03-16 | 新疆特丰药业股份有限公司 | 孟鲁司特钠咀嚼片及其粉末直接压片制备方法 |
CN104840427B (zh) * | 2014-02-13 | 2017-09-29 | 长春海悦药业股份有限公司 | 一种含有孟鲁司特钠的药物组合物 |
KR101892340B1 (ko) * | 2015-03-13 | 2018-08-27 | 경희대학교 산학협력단 | 몬테루카스트의 생체이용률을 개선시키기 위한 방법 |
JP6489435B2 (ja) * | 2015-04-20 | 2019-03-27 | 高田製薬株式会社 | モンテルカストナトリウム顆粒製剤 |
CN107595783A (zh) * | 2017-06-01 | 2018-01-19 | 合肥远志医药科技开发有限公司 | 一种孟鲁司特钠颗粒及其制备方法 |
CN109833302A (zh) * | 2017-11-29 | 2019-06-04 | 扬子江药业集团有限公司 | 一种稳定的孟鲁司特钠咀嚼片及其制备方法 |
CN110787139A (zh) * | 2018-08-01 | 2020-02-14 | 北京万全德众医药生物技术有限公司 | 一种孟鲁司特钠药物组合物 |
AU2019334202A1 (en) | 2018-09-06 | 2021-03-25 | Innopharmascreen, Inc. | Methods and compositions for treatment of asthma or parkinson's disease |
CN111110679A (zh) * | 2018-10-31 | 2020-05-08 | 长春海悦药业股份有限公司 | 一种含有孟鲁司特钠的药物组合物 |
CN111249238A (zh) * | 2020-01-19 | 2020-06-09 | 安徽省先锋制药有限公司 | 一种孟鲁司特钠颗粒制剂方法 |
US11844792B2 (en) * | 2020-07-10 | 2023-12-19 | Sean Downing | Treatment for severe acute respiratory illness associated with coronavirus |
CN111840233B (zh) * | 2020-07-29 | 2022-05-06 | 浙江诺得药业有限公司 | 一种孟鲁司特钠固体分散体、其制备方法及其应用 |
CN114224847B (zh) * | 2021-12-07 | 2023-09-15 | 哈尔滨珍宝制药有限公司 | 一种孟鲁司特钠颗粒的制备方法 |
CN114425040A (zh) * | 2022-02-24 | 2022-05-03 | 佑华医药科技有限公司 | 一种孟鲁司特钠颗粒的制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1561301A (en) * | 1976-01-02 | 1980-02-20 | Beecham Group Ltd | Orally administrable pharmaceutical composition |
CA1338596C (en) | 1988-09-27 | 1996-09-17 | Hiroyoshi Koyama | Granules having core and their production |
FI894611A (fi) | 1988-09-30 | 1990-03-31 | May & Baker Ltd | Granulaera farmaceutiska preparat. |
DE69005679T2 (de) * | 1989-03-29 | 1994-06-23 | Takeda Chemical Industries Ltd | Zusammensetzung mit einer Verbindung der Vitamin B-Gruppe und ihre Herstellung. |
JP2800242B2 (ja) | 1989-03-30 | 1998-09-21 | 大正製薬株式会社 | 粒剤の製造方法 |
US5565473A (en) * | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
JP2820829B2 (ja) | 1991-03-07 | 1998-11-05 | 武田薬品工業株式会社 | 有核散剤およびその製造方法 |
JPH0967247A (ja) | 1995-08-31 | 1997-03-11 | Taisho Pharmaceut Co Ltd | 均一な微粒子製剤の製造方法 |
WO1997016173A1 (en) * | 1995-11-02 | 1997-05-09 | Merck Frosst Canada Inc. | New technology for wet granulation |
US5869098A (en) | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
DE69835103T2 (de) | 1997-12-23 | 2006-12-21 | Schering Corp. | Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum |
US6224907B1 (en) * | 1998-03-06 | 2001-05-01 | Alza Corporation | Anti-asthma therapy |
US6103735A (en) * | 1998-10-09 | 2000-08-15 | Schering Corporation | Composition and method for treating allergic diseases |
US6221880B1 (en) * | 1998-10-09 | 2001-04-24 | Schering Corporation | Composition and method for treating allergic diseases |
AT413647B (de) | 1998-11-26 | 2006-04-15 | Sandoz Ag | Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6491949B2 (en) * | 2000-01-14 | 2002-12-10 | Osmotica Corp. | Osmotic device within an osmotic device |
US20030031720A1 (en) | 2000-02-24 | 2003-02-13 | Tobias Laich | Method for producing pharmaceutical dosage forms |
US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
-
2002
- 2002-10-17 MY MYPI20023875A patent/MY148466A/en unknown
- 2002-10-22 ES ES02801836T patent/ES2298431T3/es not_active Expired - Lifetime
- 2002-10-22 DK DK02801836T patent/DK1441701T3/da active
- 2002-10-22 MX MXPA04003856A patent/MXPA04003856A/es active IP Right Grant
- 2002-10-22 KR KR1020047006095A patent/KR101094084B1/ko active IP Right Review Request
- 2002-10-22 WO PCT/CA2002/001604 patent/WO2003035036A1/en active IP Right Grant
- 2002-10-22 DE DE60225040T patent/DE60225040T2/de not_active Expired - Lifetime
- 2002-10-22 IL IL16129902A patent/IL161299A0/xx unknown
- 2002-10-22 AT AT02801836T patent/ATE385781T1/de active
- 2002-10-22 AU AU2002333134A patent/AU2002333134B2/en not_active Expired
- 2002-10-22 BR BR0213477-2A patent/BR0213477A/pt active Pending
- 2002-10-22 PT PT02801836T patent/PT1441701E/pt unknown
- 2002-10-22 CA CA002463947A patent/CA2463947C/en not_active Expired - Lifetime
- 2002-10-22 SI SI200230670T patent/SI1441701T1/sl unknown
- 2002-10-22 HU HU0401670A patent/HUP0401670A3/hu unknown
- 2002-10-22 JP JP2003537603A patent/JP4420671B2/ja not_active Expired - Lifetime
- 2002-10-22 CN CN02821212A patent/CN100591329C/zh not_active Expired - Lifetime
- 2002-10-22 EP EP02801836A patent/EP1441701B1/en not_active Revoked
- 2002-10-23 EG EG2002101164A patent/EG24380A/xx active
- 2002-10-24 PE PE2002001047A patent/PE20030638A1/es active IP Right Grant
- 2002-10-24 US US10/279,595 patent/US20030096840A1/en not_active Abandoned
-
2004
- 2004-04-01 ZA ZA2004/02584A patent/ZA200402584B/en unknown
- 2004-04-23 EC EC2004005082A patent/ECSP045082A/es unknown
- 2004-04-23 HR HRP20040367AA patent/HRP20040367B1/xx not_active IP Right Cessation
- 2004-05-25 NO NO20042167A patent/NO20042167L/no not_active Application Discontinuation
-
2008
- 2008-02-07 US US12/069,124 patent/US8007830B2/en not_active Expired - Fee Related
- 2008-04-17 CY CY20081100434T patent/CY1107400T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EG24380A (en) | Granule formulation | |
AU3652102A (en) | Compounds and their uses | |
MXPA03010134A (es) | Derivados de ciclohexan-1-4-diamina sustituidos. | |
TW200510325A (en) | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
TNSN07235A1 (en) | Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride | |
HK1076605A1 (en) | Formulations | |
IL150257A0 (en) | Galactomaninan oligosaccharides, pharmaceutical compositions containing the same and methods for the production thereof | |
HK1077059A1 (en) | Salt of (s)-pantoprazole and its hydrates (s)- | |
AP1787A (en) | Novel perindopril salt and pharmaceutical compositions containing same. | |
DK1458377T3 (da) | Farmaceutiske sammensætninger indeholdende tegaserod | |
ZA200404752B (en) | 6-aminomorphinane derivatives method for the production and use thereof | |
PL374080A1 (en) | Processes for the preparation of fibrinogen | |
MXPA03010158A (es) | Sulfonamidas. | |
WO2002024695A3 (en) | Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines | |
SE0200657D0 (sv) | Novel Formulation | |
MXPA04004090A (es) | Compuestos substituidos de 1h-quinolin-2-ona. | |
TNSN06013A1 (en) | Semi-solid systems containing azetidine derivatives | |
MXPA04003910A (es) | Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar. | |
DE60212130D1 (en) | Carvedilolpolymorph | |
PL359727A1 (en) | Crystalline pharmaceutical | |
MXPA03001440A (es) | Compuestos de trioxepano novedosos. | |
MXPA04006085A (es) | Compuestos de isocromano para el tratamiento de trastornos del sistema nervioso central. | |
GB0109520D0 (en) | Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as njk-inhibitors |